FDA Action Update, January 2026: Approvals, Acceptance, and Clearance NeurologyLive Clinical Neurology News and Neurology Expert Insights The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what GHK CU: 100mg Supernova Peptides Dr Jonas Programs FDA Peptide Reclassification 2026 Amanecia Health GHK Cu (Copper Peptide) Therapy in South Florida Prescription Consultation & Medical Evaluation Telehealth Florida Surgery & Weight Loss Center